| Entry |
|
|---|
| Name |
Efalizumab (USAN/INN);
Raptiva (TN) |
|---|
| Remark |
|
|---|
| Efficacy |
Antipsoriatic, Immunosuppressant, Anti-CD11a antibody |
|---|
| Type |
Monoclonal antibody |
|---|
| Comment |
Treatment of transplant rejections
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04514 | Cell adhesion molecule (CAM) interaction |
| hsa04650 | Natural killer cell mediated cytotoxicity |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AG Monoclonal antibodies
L04AG02 Efalizumab
D03959 Efalizumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: other families
Integrins
ITGAL (CD11A)
D03959 Efalizumab (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
